A recent ruling from the U.S. District Court has blocked Colorado from implementing a price cap on Amgen's widely used drug, Enbrel.
This decision is significant as Enbrel is a major revenue source for Amgen, raising questions about the future of drug pricing regulations.
The ruling may have broader implications for how states can regulate pharmaceutical pricing, particularly for high-revenue drugs.
Updates
Update at 13:25 UTC on 2026-07-02
STAT reported U.S. judge blocked a Colorado state panel from placing a cap on the price of Amgen's blockbuster drug Enbrel.
Sources: STAT